{
    "id": 17092,
    "fullName": "BCR - FGFR1",
    "impact": "fusion",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "BCR - FGFR1 results from the fusion of BCR and FGFR1, resulting in an ability to transform in cell culture (PMID: 11739186) and therefore, is predicted to confer a gain of function.",
            "references": [
                {
                    "id": 4459,
                    "pubMedId": 11739186,
                    "title": "The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11739186"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 613,
        "geneSymbol": "BCR",
        "terms": [
            "BCR",
            "ALL",
            "BCR1",
            "CML",
            "D22S11",
            "D22S662",
            "PHL"
        ]
    },
    "variant": "BCR - FGFR1",
    "createDate": "01/24/2016",
    "updateDate": "07/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 2260,
                "geneSymbol": "FGFR1",
                "terms": [
                    "FGFR1",
                    "bFGF-R-1",
                    "BFGFR",
                    "CD331",
                    "CEK",
                    "ECCL",
                    "FGFBR",
                    "FGFR-1",
                    "FLG",
                    "FLT-2",
                    "FLT2",
                    "HBGFR",
                    "HH2",
                    "HRTFDS",
                    "KAL2",
                    "N-SAM",
                    "OGD"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 20788,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells from a patient with B-cell acute lymphocytic leukemia harboring BCR-FGFR1 were resistant to treatment with Iclusig (ponatinib) in culture (PMID: 31980503).",
            "molecularProfile": {
                "id": 17379,
                "profileName": "BCR - FGFR1"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60592,
                "name": "B-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18041,
                    "pubMedId": 31980503,
                    "title": "Functional characterization of two rare BCR-FGFR1+ leukemias.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31980503"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6183,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited proliferation and induced apoptosis in BCR-FGFR1 transformed cells in culture (PMID: 22875613).",
            "molecularProfile": {
                "id": 17379,
                "profileName": "BCR - FGFR1"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5786,
                    "pubMedId": 22875613,
                    "title": "Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22875613"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20782,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with acute myeloid leukemia harboring BCR-FGFR1 achieved a complete response with a negative minimal residual disease status when treated with Nexavar (sorafenib), however, eventually relapsed after an allogenic stem cell transplant (PMID: 31980503).",
            "molecularProfile": {
                "id": 17379,
                "profileName": "BCR - FGFR1"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18041,
                    "pubMedId": 31980503,
                    "title": "Functional characterization of two rare BCR-FGFR1+ leukemias.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31980503"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20787,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells from a patient with B-cell acute lymphocytic leukemia harboring BCR-FGFR1 were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 31980503).",
            "molecularProfile": {
                "id": 17379,
                "profileName": "BCR - FGFR1"
            },
            "therapy": {
                "id": 721,
                "therapyName": "Dovitinib",
                "synonyms": null
            },
            "indication": {
                "id": 60592,
                "name": "B-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18041,
                    "pubMedId": 31980503,
                    "title": "Functional characterization of two rare BCR-FGFR1+ leukemias.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31980503"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20785,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells from a patient with acute myeloid leukemia harboring BCR-FGFR1 were sensitive to treatment with Dovitinib (TKI258) in culture, demonstrating inhibition of cell growth (PMID: 31980503).",
            "molecularProfile": {
                "id": 17379,
                "profileName": "BCR - FGFR1"
            },
            "therapy": {
                "id": 721,
                "therapyName": "Dovitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18041,
                    "pubMedId": 31980503,
                    "title": "Functional characterization of two rare BCR-FGFR1+ leukemias.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31980503"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20789,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells from a patient with B-cell acute lymphocytic leukemia harboring BCR-FGFR1 were sensitive to treatment with GSK1838705A in culture, demonstrating inhibition of cell growth (PMID: 31980503).",
            "molecularProfile": {
                "id": 17379,
                "profileName": "BCR - FGFR1"
            },
            "therapy": {
                "id": 2739,
                "therapyName": "GSK1838705A",
                "synonyms": null
            },
            "indication": {
                "id": 60592,
                "name": "B-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18041,
                    "pubMedId": 31980503,
                    "title": "Functional characterization of two rare BCR-FGFR1+ leukemias.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31980503"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6186,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited colony growth in cells derived from patients with 8p11 myeloproliferative syndrome harboring BCR-FGFR1 in culture (PMID: 22875613).",
            "molecularProfile": {
                "id": 17379,
                "profileName": "BCR - FGFR1"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2226,
                "name": "myeloproliferative neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5786,
                    "pubMedId": 22875613,
                    "title": "Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22875613"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20786,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells from a patient with acute myeloid leukemia harboring BCR-FGFR1 were sensitive to treatment with RAF265 in culture, demonstrating inhibition of cell growth (PMID: 31980503).",
            "molecularProfile": {
                "id": 17379,
                "profileName": "BCR - FGFR1"
            },
            "therapy": {
                "id": 884,
                "therapyName": "RAF265",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18041,
                    "pubMedId": 31980503,
                    "title": "Functional characterization of two rare BCR-FGFR1+ leukemias.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31980503"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20784,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells from a patient with acute myeloid leukemia harboring BCR-FGFR1 were sensitive to treatment with Iclusig (ponatinib) in culture, demonstrating inhibition of cell growth (PMID: 31980503).",
            "molecularProfile": {
                "id": 17379,
                "profileName": "BCR - FGFR1"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18041,
                    "pubMedId": 31980503,
                    "title": "Functional characterization of two rare BCR-FGFR1+ leukemias.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31980503"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 17379,
            "profileName": "BCR - FGFR1",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}